A comparative study of different concentrations of topical bevacizumab on the recurrence rate of excised primary pterygium: a short-term follow-up study.
The present study was undertaken to compare the pterygium recurrence rates after treatment with two different concentrations of topical bevacizumab in those who had undergone a primary pterygium excision. The 90 patients who underwent pterygium excision were enrolled in this prospective, placebo-controlled double-blinded interventional case series. The participants were randomly categorized into 3 groups each consisting of 30 subjects. 24 h after surgery, Group II and Group III received a total of 5 and 10 mg/mL dose of topical bevacizumab, respectively; whereas patients in Group I were administered only a placebo starting a day after surgery. Participants were instructed to instill their topical medicines 4 times a day for 1 week. The patients were examined for pterygium recurrence and complications at postoperative 1, 7, and 14 days as well as each month during the following year. Pterygia recurred in 14 patients (46.7 %) in Group I and in 4 patients (13.3 %) in Group II. No recurrence was observed in Group III during the follow-up period. The Kaplan-Meier survival analysis disclosed a significantly better outcome for those who had been treated with 10 mg/mL concentrations of bevacizumab (Mantel-Cox log rank analysis, P < 0.001). The mean recurrence time was not significantly different between Group I and Group II. No ocular or systemic complication developed till the end of follow-up. Thus, 10 mg/mL concentration of topical bevacizumab was more efficacious than 5 mg/mL dose in preventing pterygium recurrence.
Department of Ophthalmology, Medical University of Urmia, 57147-83734, Urmia, Iran.
Qader
Q
Motarjemizadeh
Department of Ophthalmology, Medical University of Urmia, 57147-83734, Urmia, Iran. n.samadiadnl@gmail.com.
Naser Samadi
NS
Aidenloo
Department of Ophthalmology, Medical University of Urmia, 57147-83734, Urmia, Iran.
Siamak
S
Sepehri
D000287:Administration, Topical; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage*; D011446:Prospective Studies; D011625:Pterygium / Q000188:drug therapy* / Q000601:surgery; D012008:Recurrence
D020533:Angiogenesis Inhibitors; D009883:Ophthalmic Solutions; D000068258:Bevacizumab
Bare sclera; Bevacizumab; Iran; Pterygium; Recurrence